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Background: Skin neurofibromas represent one of the main clinical manifestations of neurofibromatosis 1, and
their number varies greatly between individuals. Quantifying their number is an important step in the methodology
of many clinical studies, but counting neurofibromas one by one in individuals with thousands of tumors is
arduous, time-consuming, and subject to intra and interexaminer variability. We aimed to evaluate the efficacy of a
new methodology for skin neurofibromas quantification using paper frames.
Methods: The sample comprised 92 individuals with NF1. Paper frames, with a central square measuring 100 cm2,
were placed on the back, abdomen and thigh. Images were taken, transferred to a computer and two independent
examiners counted the neurofibromas. The average number of neurofibromas/100 cm2 of skin was obtained from
the mean of the three values. The differences in the quantity of neurofibromas counted by two examiners were
evaluated with Intraclass correlation coefficient (ICC), paired t-test, Bland-Altman and survival-agreement plots. To
evaluate the predictive value of the method in obtaining the total number of neurofibromas, 49 participants also
had their tumors counted one by one. Reproducibility was assessed with Pearson’s correlation coefficients and
simple linear regression model.
Results: There was excellent agreement between examiners (ICC range 0.992-0.997) and the total number of skin
neurofibromas could be predicted by the adhesive frames technique using a specific formula (P < 0.0001).
Conclusions: In this article we describe a reliable, easy and rapid technique using paper frames to quantify skin
neurofibromas that accurately predicts the total number of these tumors in patients with NF1. This method may be
a useful tool in clinical practice and clinical research to help achieve an accurate quantitative phenotype of NF1.
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Neurofibromatosis 1 (NF1, OMIM 162200) is a common
autosomal dominant genetic disorder caused by mutations
in the NF1 gene. It presents extremely variable expressivity
and can cause diverse clinical manifestations, including
café-au-lait spots, axillary and inguinal freckling, Lisch
nodules, and multiple benign peripheral nerve sheath
tumors called neurofibromas [1,2]. Neurofibromas occur* Correspondence: karingcunha@gmail.com
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unless otherwise stated.mainly in cutaneous and subcutaneous tissues, usually
begin to appear during puberty and their number tends to
increase progressively with age [1,3]. To date, although
drug trials have been initiated looking for medications that
halt or slow the growth of neurofibromas, no beneficial
therapy is known.
The number of skin neurofibromas varies widely be-
tween individuals (from a few to more than thousands),
even between individuals from the same family. Cur-
rently, only two genotype-phenotype correlations are
well established: individuals with deletion of the entire
NF1 gene tend to have a large number and early devel-
opment of skin neurofibromas; those with a 3-baseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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not develop cutaneous neurofibromas [4-7]. It has been
suggested that other factors may contribute to this vari-
able expression, such as hormones, epigenetic alter-
ations, as well as modifier genes not related to the NF1
locus itself [8-11].
Quantifying the number of neurofibromas is important
for genotype-phenotype studies [12] and also for future
clinical trials of medications intended to treat skin neuro-
fibromas. Counting neurofibromas one by one in individ-
uals with NF1 who may have thousands of tumors is
arduous, time-consuming, and subject to intra- and inter-
examiner variability. In many studies, NF1 individuals are
categorized according the number of neurofibromas, and
some authors do not report if the categorization was per-
formed based on counting neurofibromas one by one or if
the exact number of tumors was not obtained and an es-
timative of their number was used, which of course is also
subject to variability [3,12-16].
Our aim was to evaluate the efficacy of a new method-
ology for skin neurofibromas quantification using paper
frames, investigating interexaminer reliability and value of
the approach in predicting the total number of skin tumors.
Methods
Case selection
This study protocol was approved by the Review Board of
the Antônio Pedro University Hospital of Universidade
Federal Fluminense, Niterói, RJ, Brazil (#121/11). The in-
dividuals’ written, informed consent was obtained and the
Declaration of Helsinki protocols were followed. A total of
92 post-pubertal NF1 individuals were included in this re-
search. NF1 diagnosis was based on the clinical criteria of
National Institutes of Health [2]. The exclusion criteria
were: presence of a large plexiform neurofibroma on the
back, thigh, or abdomen that crossed the midline; history
of surgical removal of a large number of skin neurofibro-
mas from back, thigh, or abdomen (more than ten within
the five years prior to enrollment in the study); previous
treatment with chemotherapy or radiotherapy, as well as
with any drug (such as interferon, retinoic acid, thalido-
mide, or farnesyl transferase inhibitor) tested for efficacy
in neurofibroma treatment.
Study design
After signing the informed consent, study participants had
their data collected: age, gender and skin color. Then, the
study participants were clinically evaluated after getting
undressed, keeping only their lower underwear.
Quantification of neurofibromas using the paper frames
method
The quantification technique uses paper frames, with a
central square measuring 100 cm2, which are placed inthree specific areas of the body (back, abdomen and
thigh) (Figure 1A). After placing the paper frames on the
specific areas, two photographs were taken from each
paper frame, using a digital camera (Sony Cyber-shot
DSC-W30, Tokyo, Japan). Then, to facilitate the analysis
of the photographs, a washable pen was used to mark
the cutaneous neurofibromas, as well as the subcutane-
ous neurofibromas (with the aim to facilitate their dis-
tinction from café-au-lait spots). Two additional pictures
were taken after marking the neurofibromas. The photo-
graphs were obtained with resolution of 300 dpi in JPEG
format.
The images were transferred to a computer and the
clearest photograph containing the neurofibromas marked
with the washable pen was used to count the tumors
(Figure 1B). All the pictures were analyzed using the soft-
ware Paint® (Microsoft Corporation, Redmond, WA, USA).
The examiner used the spray tool to highlight the skin
neurofibromas that had already been counted, avoiding
the possibility of counting the same neurofibroma twice
(Figure 1C). The average number of skin neurofibromas
per 100 cm2 of skin was defined as the mean of the three
areas.
Evaluation of interexaminer reliability of the paper frames
method
To evaluate the interexaminer reliability of quantification
of neurofibromas using the paper frames method, all the
pictures were analyzed by two independent trained exam-
iners: RMA (examiner A) and RERM (examiner B). The
interexaminer analysis was calculated using the mean of
the three counts (abdomen, back and thigh).
Evaluation of paper frame method in predicting the total
number of skin neurofibromas
To evaluate the predictive value of the paper frames
method in obtaining the total number of skin neuro-
fibromas, 49 participants of the study had their tumors
counted one by one by a trained examiner (RMA; exam-
iner A). Neurofibromas on genitals and scalp were not
included.
Statistical analysis
For statistical analysis, we used the SPSS software (IBM®
SPSS®, v. 20.0, Armonk, NY, USA) and Excel 2011 (Micro-
soft Corporation, Redmond, WA, USA). P values less than
0.05 were considered statistically significant. Pearson’s cor-
relation coefficient was used to evaluate the correlation
between total number of skin tumors and age of NF1 pa-
tients. For this, patients were grouped into five categories
of age: <20, 20–29, 30–39, 40–49 and ≥50 years old. For
trend across ordering, the Mann-Whitney test was used to
evaluate which age groups had significant difference in
neurofibroma quantity.
Figure 1 Paper frames method for counting skin neurofibromas. (A) Schematic image of paper frames attachment: An adhesive backing
from paper frame was removed and it was placed on the individual’s abdomen with a bottom corner placed just left of the individual’s
umbilicus, left thigh and back with the top corners put just under the individual’s scapula. If a large plexiform tumor existed on the left side of
the abdomen or thigh, the opposite side would have chosen for paper frames attachment. (B) The paper frame in the back presenting skin
neurofibromas marked by washable pen. (C) The process of skin neurofibromas counting using Paint® software (yellow points represent
neurofibromas that had already been counted).
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Table 1 Descriptive statistics and interexaminer reliability of
number of neurofibromas using the paper frame’s method
Descriptive statistics Examiner A Examiner B Differences (A-B)
n 92 92
Mean 67.09 66.17 0.93
Standard Deviation 76.79 72.67 7.47
Minimum 0 0 - 13
First Quartile 9.33 9.49 - 0.92
Median 38.49 38.99 0
Third Quartile 94.24 91.91 0
Maximum 348.66 330.66 42
Interexaminers
ICC1 0.995 (0.992 – 0.997)
P-value (Paired t test) 0.236
1= Intraclass correlation coefficient (95% confidence interval) – two-way mixed
ANOVA model, using the average of two measures (examiner A and examiner B).
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by the two independent examiners was analyzed by ICC,
Bland-Altman plot associated with Spearman’s rho cor-
relation coefficient and survival-agreement plot [17,18].
The paired t-test was also used to compare the means of
the two examiners. For interexaminer reliability analyses,
the results were also evaluated separately according to
the skin color of the NF1 individuals and according to
the average number of neurofibromas per 100 cm2
(<100 and ≥100 neurofibromas) with the aim to identify
any fixed/proportional bias. The log rank test was ap-
plied in the survival-agreement plot to evaluate the dif-
ference in the quantity of neurofibromas obtained by
both examiners according to skin color.
To estimate the inter-method reliability, Pearson’s cor-
relation coefficient was used to evaluate whether the
average number of neurofibromas in the paper frames
corresponded to the estimated number of neurofibromas
per 100 cm2 of skin based on the total number of neuro-
fibromas. To obtain the estimated number of neuro-
fibromas per 100 cm2 of skin based on the total number
of neurofibromas, we used Mosteller’s formula to calcu-
late the body surface area (BSA) [19]. BSA is defined as
the square root of height (in centimeters) multiplied by
weight (in kilograms) divided by 3,600.
The simple linear regression model was used to build
an equation for predicting the approximate total number
of skin neurofibromas from the paper frames method.
The independent variable was assigned by exact total
number of skin neurofibromas (y) and the dependent
variable by paper frames method (x). This analysis was
taken separately for each examiner. The R squared coef-
ficient (R2) was used to verify the proportion of predict-
ive values that were similar to the exact total number of
tumors. Then, a simple linear regression model (y = α + βx)
was used to convert the number of skin neurofibromas
from the paper frame method into an exact total number
of tumors [20].
Results
Details of the clinical data and count of the skin
neurofibromas of all individuals analyzed are shown in
Additional file 1. Of the 92 individuals included in this
study, 62 (67%) were females and 30 (33%) were males;
61 (66%) were white and 31 (35%) were black. The mean
age was 40.6 (± 15.6) years (range 12–77 years). Of the 49
individuals who also had the total number of neurofibro-
mas evaluated, 29 (59%) were females and 20 (41%) males;
26 (53%) were white and 23 (47%) were black. The mean
age was 35.6 (± 15.2) years (range 12–75 years).
Regarding these 49 NF1 individuals who also had the
total number of neurofibromas evaluated, the number of
tumors strongly varied with age (r = 0.633, P < 0.0001);
older individuals had higher number of neurofibromas.This variation of the number of neurofibromas accord-
ing to age occurred until 39 years old (P ≤ 0.05). After
40 years old, no differences in neurofibroma number be-
tween ages were observed (P > 0.05). The total number
of skin neurofibromas ranged from no tumors to 3,816
neurofibromas (485 ± 801; first quartile = 33, median = 183;
third quartile = 515). Eighty-four percent of individuals
had fewer than 1,000 neurofibromas and 16% had more
than 1,000 neurofibromas; of which 4% had more than
3,000 tumors. The estimated number of neurofibromas
per 100 cm2 of skin, based on the total number of neuro-
fibromas, varied from 0 to 26.7 (2.9 ± 5.2, first quartile = 0.2,
median = 1.1, third quartile = 3).Interexaminer reliability using paper frames method
There was no statistically significant difference when
comparing the general means of the number of neuro-
fibromas obtained from examiner A and examiner B
(paired t-test; P = 0.236). The intraclass correlation coef-
ficient (ICC) showed excellent homogeneity/reliability
between the two examiners (Table 1).
The results in Figure 2A show that, although the limits
of agreement were obtained between both examiners,
the examiner A tended to obtain higher values for the
count of neurofibromas using the paper frames method.
This discrepancy was more evident in individuals with
more than 100 skin neurofibromas. Therefore, we de-
cided to build Bland-Altman plots for two groups of par-
ticipants: < 100 neurofibromas and ≥ 100 neurofibromas
(Figure 2B and C, respectively). While in individuals
with < 100 neurofibromas there was a fixed bias, counting
errors in individuals with ≥ 100 neurofibromas tended to
be higher as the number of skin neurofibromas increased
Figure 2 Bland-Altman plot for the comparison between
examiner A and examiner B using paper frames method. (A) All
sample of NF1 patients (n = 92); (B) Patients with < 100 neurofibromas
from paper frames method (n = 72); (C) Patients with≥ 100
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Figure 3 Survival-agreement plot for examiner A and examiner B
using paper frames method (n = 92). (A) According to white (n = 61)
and black (n = 31) skin color of patients with NF1; (B) According to
the number of neurofibromas per 100 cm2 of skin: < 100 neurofibromas
(n = 72) and≥ 100 neurofibromas (n = 20).
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tween the differences and averages from both examiners
were seen for individuals with more than 100 neurofibro-
mas; thus the construction of the proposed limits by Bland
and Altman were lost [17,21,22].
For individuals with < 100 neurofibromas, upper and
lower limits of agreement were calculated: −0.46 (mean
difference) ± 2 × 2.32 (standard deviation difference),
resulting in an interval of −5.11 to 4.18. There was asimilar distribution of white and black individuals, accord-
ing to Bland and Altman plot (95% limits of agreement).
The survival-agreement plot demonstrated agreement
between the two examiners using the paper frames
method [18]. In Figure 3A, when a threshold of 10
neurofibromas was seen, an agreement higher than 90%
could be achieved. When the threshold of 20 neurofibro-
mas was achieved, the agreement between A and B ex-
aminers was equal, being around 96%. As the difference
of number of neurofibromas progressively increased, an
agreement of almost 100% would be observed with a
threshold of 36 neurofibromas in white individuals and
40 neurofibromas in black individuals (Figure 3A). There-
fore, no important difference of agreement between
the individuals’ skin color was observed (log rank test,
P = 0.926).
Both examiners classified six individuals as having no
skin neurofibromas, 66 (examiner A) and 65 (examiner
B) with <100 neurofibromas and 20 (examiner A) and
21 (examiner B) with ≥100 neurofibromas, showing a
Cunha et al. Orphanet Journal of Rare Diseases 2014, 9:202 Page 6 of 8
http://www.ojrd.com/content/9/1/202similar distribution according to the second survival-
agreement plot (Figure 3B). The agreement between ex-
aminers, using the paper frame method, was better for
individuals with <100 neurofibromas (maximum thresh-
old of 10 neurofibromas) than for individuals with ≥100
tumors (maximum threshold of 42 neurofibromas), but
these differences did not have clinical importance since
there was an agreement of approximately 99%.
Predictive value of paper frames method of quantification
of neurofibromas
There was a statistically significant correlation (P <0.0001)
between the average values (examiners A and examiner B)
of skin neurofibromas from paper frames method and the
estimated number of neurofibromas per 100 cm2 of skin,
based on the total number of neurofibromas. The use of
the linear regression model coefficients (α and β) predicted
the values of Y [20]. Therefore, from a methodological
point of view, the mean number of skin neurofibromas
obtained from the paper frames corresponded to the total
number of skin neurofibromas (P <0.0001), using the
equation 65.6 + 9.7× for examiner A (R2 = 0.63) and the
equation 38.6 + 10.3× for examiner B (R2 = 0.64) (Figure 4).
The linear regression plot indicates a good predictive value
for the paper frames method, having an excellent repre-
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Figure 4 Scatterplot of the total number of neurofibromas
versus number of neurofibromas from paper frames method.
Examiner A: the regression line has the intercept α = 65.6 and the
slope β = 9.7 (n = 49); Examiner B: the regression line has the
intercept α = 38.6 and the slope β = 10.3 (n = 49). There is a
statistically significant association (P < 0.0001) between the exact
total number of skin neurofibromas and paper frames method for
both examiners. Abbreviations: R2 = coefficient of determination.Discussion
We have demonstrated a new method to quantify skin
neurofibromas in NF1 individuals using three paper
frames with a 100 cm2 counting area. We showed that
this method can predict the total number of skin neuro-
fibromas and also presents a great interexaminer reliabil-
ity because an acceptable agreement is assessed for ICC
values ≥0.75; thus an excellent reproducibility is achieved
for values close to +1 [23,24]. A very high ICC (0.995)
value and a small interexaminer mean difference, which
was less than one neurofibroma (−0.92), was observed.
We measured the interexaminer reliability based on the
differences between examiners, using ICC, which is a test
that reflects the variability in mean score due to differ-
ences among examiners and how much variability is due to
differences between examiners [25]. Although the Pear-
son’s correlation coefficient is frequently used to represent
interexaminer reliability, this measure should be discour-
aged because it can be inconsistent [25].
Proportional bias could represent a practical problem
of evaluating methods because one examiner may obtain
consistently higher or lower number of neurofibromas
than the other [17]. Bland-Altman and survival-agreement
plots illustrate the information about possible fixed/pro-
portional bias and degree of agreement/disagreement be-
tween examiners, respectively. We used these tests to
investigate a possible proportional bias in individuals with
≥100 neurofibromas from the paper frames method be-
cause examiner A had a tendency to count fewer neuro-
fibromas than examiner B in individuals with more than
100 tumors. Counting differences may occur due the
superposition of the neurofibromas, which is commonly
observed in areas with a high concentration of tumors,
such as the torso [1]. Although this proportion could be
confirmed by significant association between the differ-
ences and means of examiners on the Bland-Altman plot,
this discordance (of up to 10 neurofibromas threshold)
should be interpreted as a negligible value in obtaining the
final number of skin neurofibromas, since there was a
good agreement (approximately 99%) between both exam-
iners using a survival-agreement plot [18]. In this study,
we also evaluated whether black skin color could hinder
the tumor counting. Our results showed that this variable
was not a confounding factor, since it did not cause any
proportional/fixed bias or significant difference in the
number of tumors counted by the examiners.
The results using the frames to count neurofibromas
show that this methodology may be useful for future stud-
ies with NF1 individuals. Although previous NF1 clinical
studies and case reports, as well as case studies, have in-
cluded neurofibroma quantification in their methods, the
lack of an universal approach for quantification of these
tumors is evident [3,12-16]. For example, in some studies,
neurofibromas are counted by different examiners or the
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mas is not clear in the methodology [3,12]. In retrospect-
ive studies, as pointed by Duong et al. [3], the patients’
recruitment might also bias results, since skin neurofibro-
mas would be assessed in clinical practice more accurately
by dermatologists, for example [3]. Moreover, many au-
thors do not mention which methodology was applied for
neurofibroma quantification (counting one by one or an
estimate number).
Quantifying the skin neurofibromas “one by one” may
be very difficult and time consuming and is subject to
intra- and interexaminer variation, mainly in individuals
with more than 500 tumors. Therefore, researchers and
clinicians commonly do not perform an exact count of
the skin neurofibromas. Usually, individuals are catego-
rized according to previously established count ranges,
based on an estimated number of neurofibromas achieved
by the overall clinical appearance. There are limitations
when the number of tumors is predicted only by the over-
all clinical appearance. Individuals with many but small
skin neurofibromas may have their total number of tu-
mors underestimated. In many of these studies, for statis-
tical analysis, patients are categorized in low and high
tumor number groups. In the literature, there is a great
variability in the cut-off values for the categorization of
the NF1 individuals based on the number of neurofibro-
mas. For example, the minimum value of the higher count
range of neurofibromas in previous studies varies from
≥100, > 500 to >1,000 tumors [3,12,14,15]. Taking into
consideration our NF1 sample, the number of neurofibro-
mas ranged from 0 to 3,816 tumors, showing a tremen-
dous variation. Evidently, the cut-off values of the count
range of neurofibromas to create a categorization have im-
portant influence on the results. What are the optimal
cut-off values for categorization? Future studies are neces-
sary to perform this investigation and the use of the paper
frames method may help in this research.
Our study confirms previously published data on skin
neurofibromas, indicating an increase in number with
age [3,26,27]. This is an important issue that should be
taken into consideration when evaluating the number of
skin tumors in NF1 individuals of different ages. For ex-
ample, having more than 50 neurofibromas is rare in
young adults and can be considered a high number of
tumors, but having up to 50 neurofibromas can be con-
sidered a low number of tumors in older adults. There-
fore, categorizing patients according to the number of
neurofibromas for statistical analysis should take into
consideration the age of the patients.
Individuals with NF1 present great variability not only
in number of neurofibromas, but also in size of these tu-
mors. To our knowledge, this variability in size of neuro-
fibromas has never been evaluated in previous studies
and it would be interesting to be included in futureresearch. One of the advantages of paper frames method
is the possibility of its usage, not only to evaluate the
number, but also the size of the neurofibromas. It is pos-
sible because they present circles with different diame-
ters (in millimeters) on the lateral margins. The paper
frames method can be used to perform longitudinal
studies, describing the evolution for each patient, regard-
ing the number and the size of neurofibromas, over
time. This longitudinal investigation of the number and
size of neurofibromas would be of particular interest in
drug tests.
In this study, we evaluated the cutaneous and subcuta-
neous neurofibromas together, but the number of these
tumors can be achieved separately using the paper frame
method, depending on the aims of the study. The pres-
ence of subcutaneous neurofibromas could be an expres-
sion of a more aggressive disease [28,29]. An association
between malignant peripheral nerve sheath tumors and
internal neurofibromas has been reported [29] and the
presence of internal neurofibromas has recently been as-
sociated with at least 2 subcutaneous neurofibromas [16].
Conclusions
In this article we describe a reliable, easy and rapid tech-
nique using paper frames to quantify skin neurofibromas
that accurately predicts the total number of these tu-
mors in patients with NF1. This method may be a useful
tool in clinical practice and clinical research to help
achieve an accurate quantitative phenotype of NF1. We
are now working on the automation of the skin neuro-
fibromas quantification using paper frames by pictures
computerized analysis.
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